Comparison of PD-L1 Immunostain Concordance of SP263 and SP142 Across Different Tumor Types

被引：0
|
作者：
Nakasaki, Manando [1 ]
Fadare, Oluwole [1 ]
Patel, Sandip [1 ]
Hansel, Donna [1 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
LABORATORY INVESTIGATION | 2017年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
2140
引用
收藏
页码：532A / 532A
页数：1
相关论文
共 50 条
  • [1] Comparison of PD-L1 Immunostain Concordance of SP263 and SP142 Across Different Tumor Types
    Nakasaki, Manando
    Fadare, Oluwole
    Patel, Sandip
    Hansel, Donna
    MODERN PATHOLOGY, 2017, 30 : 532A - 532A
  • [2] PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay
    Gupta, Gurudutt
    Pasricha, Sunil
    Kamboj, Meenakshi
    Sharma, Anila
    Nayana, N. S.
    Durga, Garima
    Sharma, Anurag
    Rawal, Sudhir
    Meh, Anurag
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2022, 65 (04) : 839 - 843
  • [3] PD-L1 status by SP142 and sp263 immunohistochemistry in triple-negative breast cancer
    Cordoba, A.
    Mercado, M. D. R.
    Amat, I.
    Beloqui, R.
    Aguiar, B.
    Rodriguez, Y.
    Guerrero-Setas, D.
    VIRCHOWS ARCHIV, 2020, 477 : S44 - S44
  • [4] Precision and Repeatability of the VENTANA PD-L1 (SP263) Assay Across Six Different Tumor Types
    Nielsen, Alma
    Manriquez, Guadalupe
    Hayden, Dorothy
    Lian, Fangru
    Liu, Chunyan
    Patil, Pallavi
    Wang, Peiyi
    Gu, Pengfei
    Schnittker, Karina
    Roland, Bryan
    Quiroz, Michelle
    Newell, Amy Hanlon
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 830 - 831
  • [5] Precision and Repeatability of the VENTANA PD-L1 (SP263) Assay Across Six Different Tumor Types
    Nielsen, Alma
    Manriquez, Guadalupe
    Hayden, Dorothy
    Lian, Fangru
    Liu, Chunyan
    Patil, Pallavi
    Wang, Peiyi
    Gu, Pengfei
    Schnittker, Karina
    Roland, Bryan
    Quiroz, Michelle
    Newell, Amy Hanlon
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 830 - 831
  • [6] Epitope mapping of PD-L1 primary antibodies (28-8, SP142, SP263 E1L3N).
    Schats, Kelly
    Van Vre, Emily A.
    Schrijvers, Darien
    De Meester, Ingrid
    Kockx, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Ventana PD-L1 (SP142) Assay
    McGill, Rachel
    Michail, Ramez
    Miller, Brianne
    Milton, Erica
    Musyoka, Agnes
    Musyoka, Rhoda
    O'Conner, Jada
    Ogunnaike, Morenike
    Omeke, Soteria
    Franklin, Gallop
    Honeywell, Marlon S.
    US PHARMACIST, 2022, 47 (10) : 42 - 44
  • [8] Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors.
    Oyan, Basak
    Sonmez, Ozlem
    Yazar, Aziz
    Teomet, Mehmet
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Using Sp142, Sp263 and E1L3N
    Brunelli, Matteo
    Calio', Anna
    Munari, Enrico
    Pedron, Serena
    Ciocchetta, Elisa
    Bogina, Giuseppe
    Zamboni, Giuseppe
    Martignoni, Guido
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 862 - 862
  • [10] PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Using Sp142, Sp263 and E1L3N
    Brunelli, Matteo
    Calio, Anna
    Munari, Enrico
    Pedron, Serena
    Ciocchetta, Elisa
    Bogina, Giuseppe
    Zamboni, Giuseppe
    Martignoni, Guido
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 862 - 862
12345